| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Insulin-induced Akt phosphorylation in L6 myotubes is increased by AS1949490 (0-16 μM; 15 minutes) [1]. In L6 myotubes, AS1949490 (0-10 μM; 48) induces stress and promotes trophic activity [1]. AS1949490 (0-0.10 μM; 24-hour; L6 myotubes) inhibits the gluconeogenic process triggered by insulin [1]. In L6 myotubes, AS1949490 (10 μM; 48 hours) upregulates the GLUT1 gene to initiate oxygen switching [2].
|
|---|---|
| ln Vivo |
The intracellular insulin signaling pathway is activated and the risk of diabetes in the diabetic retina is decreased by AS1949490 (300 mg/kg; Pathway; twice daily for 7 or 10 days) [1]. AS1949490 (300 mg/kg; 8-hour single dose).
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: L6 Myotubes Tested Concentrations: 0, 4, 8 and 16 μM; ]. 1 nM (insulin) Incubation Duration: 15 minutes Experimental Results: Insulin-induced Akt phosphorylation increases in a dose-dependent manner. Western Blot Analysis[2] Cell Types: L6 myotubes Tested Concentrations: 10 µM Incubation Duration: 48 hrs (hours) Experimental Results: GLUT1 mRNA expression was increased in L6 myotubes, but GLUT4 mRNA expression was not. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/KsJ Jcl-dbm mice and db/+db mice [1].
Doses: 300 mg/kg. Route of Administration: oral; ; formulated ICR s) Inhibit gluconeogenesis and the expression of related genes [1]. twice (two times) daily for 7 or 10 days Experimental Results: Decrease in plasma glucose (23% relative to vehicle). Reduction in fasting blood glucose (37% relative to vehicle) and area under the blood glucose concentration-time curve (AUC). Increases GSK3β phosphorylation in the liver without changing overall GSK3β protein levels. Animal/Disease Models: Male ICR mice (6 weeks old) [1] Doses: 300 mg/kg Route of Administration: po (po (oral gavage)) once for 8 hrs (hrs (hours)). Experimental Results: PEPCK and G6Pase mRNA levels were diminished by approximately 50%. |
| References |
|
| Molecular Formula |
C20H18CLNO2S
|
|---|---|
| Molecular Weight |
371.879
|
| Exact Mass |
371.075
|
| CAS # |
1203680-76-5
|
| PubChem CID |
44473434
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.046
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
422
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C=CS2)OCC3=CC=C(C=C3)Cl
|
| InChi Key |
RFZPGNRLOKVZJY-AWEZNQCLSA-N
|
| InChi Code |
InChI=1S/C20H18ClNO2S/c1-14(16-5-3-2-4-6-16)22-20(23)19-18(11-12-25-19)24-13-15-7-9-17(21)10-8-15/h2-12,14H,13H2,1H3,(H,22,23)/t14-/m0/s1
|
| Chemical Name |
3-[(4-chlorophenyl)methoxy]-N-[(1S)-1-phenylethyl]thiophene-2-carboxamide
|
| Synonyms |
AS1949490 AS 1949490 AS-1949490
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~134.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6890 mL | 13.4452 mL | 26.8904 mL | |
| 5 mM | 0.5378 mL | 2.6890 mL | 5.3781 mL | |
| 10 mM | 0.2689 mL | 1.3445 mL | 2.6890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
